Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | MicrobiomeTrials
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-01-09Est. Completion: 2029-02-15
Enrollment target: 85 participants
Locations
Research Site, Decatur, Illinois, United States
Research Site, New York, New York, United States
Research Site, Chapel Hill, North Carolina, United States
Research Site, Durham, North Carolina, United States
Research Site, Portland, Oregon, United States
Research Site, Houston, Texas, United States
Research Site, Fitzroy, Australia
Research Site, Perth, Australia
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Copenhagen, Denmark
Research Site, Dresden, Germany
Research Site, Frankfurt A. Main, Germany
Research Site, Halle, Germany
Research Site, Heidelberg, Germany
Research Site, München, Germany
Research Site, Ulm, Germany
Research Site, Bologna, Italy
Research Site, Ravenna, Italy
Research Site, Bunkyō City, Japan
Research Site, Kashiwa, Japan
Other microbiome trials you might be interested in